Skip to main content
TipRanks
Go Ultimate75% OFF

Greenwich LifeSciences (GLSI) Stock Statistics & Valuation Metrics

454 Followers

Total Valuation

Greenwich LifeSciences has a market cap or net worth of $290.48M. The enterprise value is $341.62T.

Market Cap
$290.48M
Enterprise Value
$341.62T

Share Statistics

Greenwich LifeSciences has 14,678,208 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
14,678,208
Owned by Insiders
38.23%
Owned by Institutions
11.77%

Financial Efficiency

Greenwich LifeSciences’s return on equity (ROE) is -54.81 and return on invested capital (ROIC) is -5505.94%.

Return on Equity (ROE)
-54.81
Return on Assets (ROA)
-3.13
Return on Invested Capital (ROIC)
-5505.94%
Return on Capital Employed (ROCE)
-55.06
Revenue Per Employee
0
Profits Per Employee
-1.49M
Employee Count
13
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Greenwich LifeSciences is -12.07. Greenwich LifeSciences’s PEG ratio is 0.98.

PE Ratio
-12.07
PS Ratio
0.00
PB Ratio
-166.29
Price to FCF
-22.70
Price to Operating Cash Flow
-22.70
PEG Ratio
0.98

Income Statement

In the last 12 months, Greenwich LifeSciences had revenue of 0 and earned -19.36M in profits. Earnings per share was -1.43.

Revenue
0
Gross Profit
-1,779
Operating Income
-19.45M
Pretax Income
-19.36M
Net Income
-19.36M
EBITDA
-19.36M
Earnings Per Share (EPS)
-1.43

Cash Flow

In the last 12 months, operating cash flow was -12.79M and capital expenditures -3, giving a free cash flow of -12.79M billion.

Operating Cash Flow
-12.79M
Free Cash Flow
-12.79M
Free Cash Flow per Share
-0.87

Dividends & Yields

Greenwich LifeSciences pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-4.53%
Earnings Yield
-8.27%

Stock Price Statistics

Beta
1.95
52-Week Price Change
143.42%
50-Day Moving Average
16.69
200-Day Moving Average
20.69
Relative Strength Index (RSI)
60.61
Average Volume (3m)
156.20K

Financial Position

Greenwich LifeSciences as a current ratio of 1.06, with Debt / Equity ratio of 0.00%

Current Ratio
1.06
Quick Ratio
1.06
Debt to Market Cap
0.00
Net Debt to EBITDA
0.32
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, Greenwich LifeSciences has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Greenwich LifeSciences EV to EBITDA ratio is -11.84, with an EV/FCF ratio of -21.59.

EV to Sales
0.00
EV to EBITDA
-11.84
EV to Free Cash Flow
-21.59
EV to Operating Cash Flow
-21.59

Balance Sheet

Greenwich LifeSciences has $5.90M in cash and marketable securities with $0.00 in debt, giving a net cash position of $5.90M billion.

Cash & Marketable Securities
$5.90M
Total Debt
$0.00
Net Cash
$5.90M
Net Cash Per Share
$0.40
Tangible Book Value Per Share
-$0.12

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin
0.00%
Operating Margin
0.00%
Pretax Margin
0.00%
Net Profit Margin
0.00%
EBITDA Margin
0.00%
EBIT Margin
0.00%

Analyst Forecast

The average price target for Greenwich LifeSciences is $70.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target
$70.00
Price Target Upside
253.71% Upside
Analyst Consensus
Moderate Buy
Analyst Count
1
Revenue Growth Forecast
―
EPS Growth Forecast
-9.87%

Scores

Smart Score
8
AI Score
―